{"entity":{"id":"nct05731271","kind":"trial","name":"A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TST003 in colorectal cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., active and no longer recruiting.","summary":"A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05731271 by Transcenta Therapeutics (Hangzhou) Co., Ltd., with 111 participants enrolled, started 2023-02-08 and due to reach its primary completion in 2026-06. Interventions recorded: TST003.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05731271","url":"https://clinicaltrials.gov/study/NCT05731271"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05731271","phase":"1/2","setting":"A First-in-Human, Open-Label, Multi-Center Phase 1 Study of TST003 in Subjects With Locally Advanced or Metastatic Solid Tumors","sponsor":"Transcenta Therapeutics (Hangzhou) Co., Ltd.","enrolled":111,"outcomes":[]},"route":"/trials/nct05731271/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"tst003","kind":"drug","name":"TST003","route":"/drugs/tst003/"}]}}